Emily thi arbutus biopharma
WebJun 2, 2024 · WARMINSTER, Pa., June 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people... WebThere are 2 professionals named "Emily Thi", who use LinkedIn to exchange information, ideas, and opportunities. ... Arbutus Biopharma Corporation, +1 more The University of British Columbia
Emily thi arbutus biopharma
Did you know?
WebJust like our namesake Arbutus, a healing plant native to North America, we are leveraging our growing innovative portfolio of assets to focus our efforts on treating and curing conditions with unmet medical need. Today, our virology pipeline has active clinical and … WebEmily Thi, Ph.D., is the Senior Director of Immunobiology and Biomarkers Research at Arbutus Biopharma where she leads the immunology, preclinical in vivo pharmacology and clinical biomarkers support for …
WebSenior Director, Virology at Arbutus Biopharma, Inc. Oreland, Pennsylvania, United States ... Today Dr. Emily Thi presented data from our lead clinical-stage HBV asset AB-729, which showed ... WebMay 20, 2024 · Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient. …
WebJun 8, 2024 · Arbutus RNAi agents ARB-1467 and ARB-1740 are currently in Phase II clinical testing in chronic HBV patients and AB-423, a capsid assembly inhibitor, is in Phase I. "Activation of STING Mediates Antiviral Effects in a Mouse Model of Chronic Hepatitis B" by Emily Thi, Principal Scientist, In Vivo Pharmacology and Macro-Molecular Discovery WebJust like our namesake Arbutus, a healing plant native to North America, we are leveraging our growing innovative portfolio of assets to focus our efforts on treating and curing conditions with unmet medical need. Today, our virology pipeline has active clinical and pre-clinical studies in the areas of Hepatitis B virus (HBV) and pan-coronavirus.
WebEmily Thi is a Senior Director, In Vivo Pharmacology and Clinical Virology at Arbutus Biopharma based in Warminster, Pennsylvania. Emily received a Doctor of Philosophy degree from The University of British Columbia.
WebMay 22, 2024 · Arbutus RNAi agents ARB-1467 and ARB-1740 are currently in Phase II clinical testing in chronic HBV patients and AB-423, a capsid assembly inhibitor, is in Phase I. "Activation of STING Mediates Antiviral Effects in a Mouse Model of Chronic Hepatitis B" by Emily Thi, Principal Scientist, In Vivo Pharmacology and Macro-Molecular Discovery christo mallakisWebPrincipal Scientist at Arbutus Biopharma Corporation. Emily Thi is the Principal Scientist at Arbutus Biopharma Corporation based in Canada. Get Emily This Contact Info christo kunstpalastchristmas vienna marketWebJun 25, 2024 · WARMINSTER, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ABUS, ... Dr. Emily Thi presented data from a poster titled, "Preclinical activity of small-molecule oral PD-L1 ... christo koulisis mdWebApr 11, 2024 · No. 20-1183 (Fed. Cir. 2024) Arbutus’s 127 patent states that its purpose is to allow for more efficient methods and compositions for introducing nucleic acids into cells and methods of downregulating gene expression. The invention is, in part, the “surprising discovery” of the Morphology Limitation when one controls two factors: the ... christo viljoenWebPrincipal Scientist @ Arbutus Biopharma Corporation; Senior Scientist, in Vivo Pharmacology and Macro-Molecular Discovery @ Arbutus Biopharma Corporation; Scientist, Research @ Arbutus Biopharma Corporation; see more Postdoctoral … christo tjahjantoWebFind Emily Thi's accurate email address and contact/phone number in Adapt.io. Currently working as Principal Scientist at Arbutus Biopharma in British Columbia, Canada. Connect with intelligence christof okulla